The Coronary Sinus Reducer; 5-year Dutch experience

Background Refractory angina is a growing and major health-care problem affecting millions of patients with coronary artery disease worldwide. The Coronary Sinus Reducer (CSR) is a device that may be considered for the relief of symptoms of refractory angina. It causes increased venous pressure lead...

Full description

Saved in:
Bibliographic Details
Published in:Netherlands heart journal 2021-04, Vol.29 (4), p.215-223
Main Authors: Silvis, M. J. M., Dekker, M., Zivelonghi, C., Agostoni, P., Stella, P. R., Doevendans, P. A., de Kleijn, D. P. V., van Kuijk, J. P., Leenders, G. E., Timmers, L.
Format: Article
Language:English
Subjects:
Angina pectoris
Cardiology
Cardiovascular disease
Coronary vessels
Ejection fraction
Hospitals
Ischemia
Medical Education
Medicine
Medicine & Public Health
Original
Original Article
Patients
Population
Quality of life
Risk factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Refractory angina is a growing and major health-care problem affecting millions of patients with coronary artery disease worldwide. The Coronary Sinus Reducer (CSR) is a device that may be considered for the relief of symptoms of refractory angina. It causes increased venous pressure leading to a dilatation of arterioles and reduced arterial vascular resistance in the sub-endocardium. This study describes the 5‑year Dutch experience regarding safety and efficacy of the CSR. Methods One hundred and thirty-two patients with refractory angina were treated with the CSR. The primary efficacy endpoint of the study was Canadian Cardiovascular Society (CCS) class improvement between baseline and 6‑month follow-up. The primary safety endpoint was successful CSR implantation in the absence of any device-related events. Results Eighty-five patients (67%) showed improvement of at least 1 CCS class and 43 patients (34%) of at least 2 classes. Mean CCS class improved from 3.17 ± 0.61 to 2.12 ± 1.07 after implantation ( P  
ISSN:1568-5888
1876-6250
DOI:10.1007/s12471-020-01525-8